Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

ANNALS OF ONCOLOGY

ELSEVIER

1. Eisai Inc., Nutley, NJ, USA
2. Merck Sharp Dohme LLC